Strong exports drive Ind-Swift profit up 15 pct

Drug-maker Ind-Swift Laboratories Limited on Thursday said it has clocked a net profit of Rs 28.44-crore in the third-quarter ended Dec 31, 2011, a 15.52 percent jump from Rs 24.62-crore in the year-ago period.

The company's total revenue in Q3FY12 has increased 15.7 percent to Rs 358.80-crore as against Rs 310.11-crore in the year-ago period.

Its EBITDA also showed a 22.44 percent growth in Q3FY12 at Rs 63.88-crore as compared to Rs 52.17-crore in the same period of the previous fiscal.

On a quarter-to-quarter (QoQ) basis as well, Ind-Swift Laboratories Limited has recorded a 27.5 percent jump in its PAT at Rs 28.44-crore (Q3 FY 12) as against Rs 22.31-crore in Q2 FY 12 while its total revenue was up 0.98 per cent to Rs 358.80-crore (Q3 FY 12) as against Rs 355.32-crore in the previous quarter.

Commenting on the Q3 FY 12 financial results, the company's Vice-Chairman cum Managing Director, N R Munjal said, "We are on the high-growth track. Our growth in profits is as per our expectations. Our growth plans for the last quarter of this year as well as over the next three- years are in place and we are confident Ind-Swift Laboratories Limited will continue to grow from strength to strength."

The company's export during the quarter also saw a jump of 75 percent, rising from Rs 102.61 crores in September 2011 to Rs. 176.55 crores in December, 2011.

Ind-Swift, that got the Korean FDA approval and Pharmaceutical & Medical Devices Agency Japan approval this year, is already supplying commercial quantities of its key molecules to the highly regulated markets of USA & Japan.